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Abstract 
Review on GSTM1, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
GSTM1; Glutathione S-transferase M1 
Identity 
Other names: GST1, GSTA, MU; H-B, GTH4, 
GTM1, MU-1, GSTM1-1, GSTM1a-1a, GSTM1b-
1b 
HGNC (Hugo): GSTM1 
Location: 1p13.3 
Location (base pair) 
Starts at 110,230,418 and ends at 110,236,367 bp 
from pter (according to hg19/Feb_2009). 
DNA/RNA 
Note 
In humans, five GSTM genes are encoded by a 100-
kb gene cluster on chromosome 1p13.3 arranged as 
5?-GSTM4-GSTM2-GSTM1-GSTM5-GSTM3-3?, 
known to be highly polymorphic (Pearson et al., 
1993). 
Description 
The GSTM1 gene is composed of 8 exons spanning 
a region of 21,244 bases, with transcript length of 
1,161 bps and translation length of 218 residues 
(according to ensembl GRCh37 release 78). The 
GSTM1 gene is approximately 20 kb in length and 
is closely flanked by other mu class gene sequences. 
The end points of the polymorphic GSTM1 deletion 
are: the left repeated region 5 kb downstream from 
the 3?-end of the GSTM2 gene and 5 kb upstream 
from the beginning of the GSTM1 gene; the right 
repeated region 5 kb downstream from the 3?-end of 
the GSTM1 and 10 kb upstream from the 5?-end of 
the GSTM5 gene (Xu et al., 1998). The cDNAs 
encoded by GSTM1 and GSTM2 share a remarkable 
99% sequence identity (Vorachek et al., 1991). The 
fact that GSTM1 and GSTM2 are physically linked 
suggests that the frequent deletion of the GSTM1 
locus is caused by unequal crossing-over (Pearson et 
al., 1993). Furthermore, in HeLa cells, it has been 
confirmed that GSTM2 overexpression, following 
transient knockdown of GSTM1 and the absence of 
GSTM1 activity, may be compensated by the 
overexpression of GSTM2 (Bhattacharjee et al., 
2013). Moreover, existence of linkage 
disequilibrium between GSTM1 and GSTM3 
suggests that association between phenotype and 
GSTM1 genotypes may also reflect polymorphism 
in GSTM3 or even other GSTM genes (Wu et al., 
2012). 
Polymorphisms: The restriction mapping data 
revealed the presence of a GST mu cluster with two 
GSTM1 genes in tandem situated between the 
GSTM2 and GSTM5 genes (McLellan et al., 1997). 
The GSTM1 gene contains four different alleles, 
leading to several M1 class polymorphisms, 
designated as GSTM1-0, GSTM1-A, GSTM1-B and 
GSTM1-1x2 alleles (Wu et al., 2012; Board PG, 
1981). GSTM1-0 (GSTM1 null allele) arose from a 
recombination event during evolution between 2 
highly homologous regions flanking this locus, 
resulting in deletion of a 20-kb segment (Xu et al., 
1998). 
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GSTM1 gene. The GSTM1 gene spans a region of 21,244 bases, composed of the eights exons (red) and seven introns (green). 
Exons 1, 2, 3, 4, 5, 6, 7 and 8 are 90bp, 76bp, 65bp, 82bp, 101bp, 96bp, 111bp and 540bp in length, respectively. 
 
This deletion produces a novel 7.4-kb HindIII 
fragment with the loss of 10.3- and 11.4-kb HindIII 
fragments, hence homozygotes for GSTM1 null 
allele produce no GSTM1 protein. The prevalence of 
GSTM1 deletion polymorphisms varies across 
ethnic groups, from 18% to 66% (median, 50%), 
with the exception of Asians, for whom it is 38%-
58% (Wu et al., 2012). GSTM1-A and GSTM1-B 
differ by a single base in exon 7 (Seidegard et al., 
1988). Namely, GSTM1-A and GSTM1-B differ by 
a C?G substitution at base position 534, resulting in 
a substitution of Lys?Asn at amino acid 172 
(Widersten et al., 1991). The substitution further 
results in formation of monodimers (GSTM1A-1A, 
GSTM1B-1B) or heterodimers (GSTM1A-1B), 
although in vitro studies suggest that their activities 
are similar (Widersten et al., 1991). In Saudi Arabian 
population, a unique GSTM1 variant dGSTM1-1x2, 
containing a duplicated GSTM1 gene has been 
identified (Evans et al., 1996). 
Transcription 
The 1161-nucleotide transcript encodes a protein of 
218 amino acid residues 
Pseudogene 
At least one other mu class GST gene or pseudogene 
exists and is found on chromosome 3, probably in 
the region 3p24-3pter (Pearson et al., 1993; 
McLellan et al., 1997). 
Protein 
Note 
Glutathione S-transferase M1 describes 2 isoforms 
produced by alternative splicing (UNIPROT). 
Description 
Amino acids: 218. Calculated molecular mass: 
25.712 Da. Isoelectric point: at pH 6.6 (Mannervik 
B, 1985). The active GSTM1 enzyme results from 
the homo- or heterodimeric combination of the 
products of the 2 alleles. Namely, in GSTM1 
examples of gene duplication, as well as, three 
alleles have been described (GSTM1 null, GSTM1-
A and GSTM1-B) (Hayes and Strange, 2000). 
GSTM1-A and GSTM1-B alleles encode proteins 
that are catalytically identical (Widersten et al., 
1991), while the null allele and gene duplication 
confer marked differences in enzyme activity (Hayes 
and Strange, 2000). This difference in enzyme 
activity is due to the fact that the null phenotype is 
characterized by an absence of near-neutral 
enzymes, whereas individuals with either GSTM1-A 
or GSTM1-B phenotype each express one near-
neutral transferase (Vos and Van Bladeren, 1990). 
Regarding the subunit composition, each subunit 
contains a glutathion-binding site (G-site) and a 
second adjacent hydrophobic-binding site for the 
electrophilic substrate (H-site) (Ji et al., 1992), 
located in a deep cavity, composed of three relatively 
mobile structural elements. Fifteen hydrogen bonds 
or salt-bridge contacts are involved in interaction 
between glutathione and enzyme (Ji et al., 1992). 
Expression 
Quantitative analysis of GSTM1 protein in various 
human tissues showed that the richest source of 
cytosolic GSTM1 is the liver. The other sources 
include testis, lungs, stomach, intestine, spleen, 
brain, kidneys, heart, breast, colon, pituitary and the 
lymphocytes (Vos and Van Bladeren, 1990; Eaton 
and Bammler, 1999). Binding of the transcription 
factor AP1 has been suggested as a common 





Human GSTM1 enzyme catalyzes the glutathione-
dependent detoxification of electrophiles, showing 
highly promiscuous substrate selectivity for many 
structurally unrelated chemicals, including 
environmental carcinogens (e.g. benzo(a)pyrene diol 
epoxides) and several chemotherapeutic agents 
(such as BCNU, brostallicin, ethacrinic acid, 
thiopurines, vincristine and chlorambucil) (Depeille 
et al., 2004; Lo and Ali-Osman, 2007). In addition to 
enzymatic detoxification, GSTM1 acts as a 
modulator of mitogen-activated protein kinase 
(MAPK) signal transduction pathway and mediates 
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apoptosis via a mechanism involving protein-protein 
interactions. Namely, GSTM1 forms complexes 
with apoptosis signal-regulating kinase 1 (ASK1), 
inhibiting ASK1 activation during cellular stress 
(Cho et al., 2001; Townsend and Tew, 2003). This 
suggests that GSTM1 might confer drug resistance 
by two distinct means: by direct inactivation 
(detoxification) of chemotherapeutic drugs and/or by 
acting as inhibitor of MAPK pathway. 
Homology 
The close physical proximity exists between the 
GSTM1 and GSTM2 loci, which share 99% 
nucleotide sequence identity over 460 nucleotides of 
3'-untranslated mRNA (Pearson et al., 1993). 
Mutations 
Germinal 
None described so far. 
Somatic 
21 mutations (COSMIC): 15 substitution-missense, 
5 substitution-synonimous, 1 unknown type. 
Implicated in 
Lung cancer 
It has been suggested that GSTM1-null genotype 
may be associated with the risk of lung cancer, 
however there is a possibility that the magnitude of 
the association varies significantly by 
characteristics, such as ethnic background (Ye et al., 
2006). Furthermore, observations from a large 
pooled analysis strongly suggest the existence of 
gene-gene interactions in lung carcinogenesis, 
leading to an increased risk of lung cancer in case of 
the double deletion of both GSTM1 and GSTT1, 
which is even more potentiated when CYP1A1-4 is 
included (Vineis et al., 2007). In studies conducted 
in populations where tobacco use is likely to be the 
primary cause of lung cancer, the GSTM1-null 
genotype was associated with a significantly 
increased lung cancer risk, as well as, in populations 
exposed to sources of indoor air pollution from 
cooking and heating (Hosgood et al., 2007). 
Breast cancer 
Only a slightly higher breast cancer risk has been 
suggested among women with GSTM1 deletion, 
more significant in post-menopausal women, as well 
as, in populations with a lower frequency of GSTM1 
deficiency (Sull et al., 2004). Further analysis 
showed that increased breast cancer risk was 
associated with GSTM1-null genotype in Caucasian 
and Asian women, suggesting GSTM1-null 
genotype as a low-penetrant risk factor for 
developing breast cancer (Qiu et al., 2010).  
The GSTM1-null genotype is also recognized as a 
risk factor for synchronous breast cancers and for 
breast cancer associated with one extramammary 
cancer (Chiril? et al., 2014). Recently, GSTM1 
polymorphism has been suggested as a prognostic 
factor in women with breast cancer (Oliveira et al., 
2014). 
Oral and pharyngeal cancers 
Although an association between the GSTM1-null 
genotype and head and neck tumors has been 
suggested, the meta-analysis of Varela-Lema et al. 
(2008) showed that GSTM1-null genotype could not 
be associated with oral and pharyngeal tumors in 
Caucasians, possibly due to the fact that previous 
meta- and pooled analysis did not analyze ethnic 
specificity.  
However, polymorphic deletion of the GSTM1 gene 
seems to markedly alter the alcohol-tobacco 
interaction, contributing to susceptibility to oral and 
pharyngeal cancer (Peters et al., 2006). 
Esophageal cancer 
There are contradictory findings regarding the role 
of GSTM1 polimorphism in susceptibility to 
esophageal cancer. Namely, it seems that ethnic 
specificity plays a role, since no significant 
association between GST genotypes and esophageal 
squamous cell or adenocarcinoma risk in Caucasian 
was found (Dura et al., 2013), while association 
between GSTM1-null genotype and risk of 
esophageal carcinoma has been confirmed in 
Chinese population (Zhong et al., 2013). 
Gastric cancer 
It has been found that GSTM1-null genotype is 
associated with increased risk of gastric cancer. 
When analyzed according to ethnicities, increased 
risk of gastric cancer was only observed in Asians, 
while no significant association was found in 
Caucasians or Latin Americans. GSTM1-null 
genotype increases susceptibility to gastric cancer 
both in ever-smokers and non-smokers, while the 
significant association was only observed in 
Helicobacter pylori positive population (Zhao et al., 
2013; Lao et al., 2014). 
Liver cancer 
GSTM1-null genotype is associated with 
significantly increased risk of hepatocellular 
carcinoma only among East Asians and Indians, 
while the association is lacking among Caucasian 
and African populations (Shen et al., 2014). This is 
further confirmed by results on association between 
GSTM1-null genotype and an increased risk of 
hepatocellular carcinoma in Chinese population (Liu 
et al., 2013). 
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Pancreatic cancer 
Available data are not sufficient to identify the 
association between the GSTM1 polymorphism and 
pancreatic cancer risk (Fan et al., 2013). 
Renal cell carcinoma 
Recent meta-analysis of 11 case-control studies 
showed that the dual null genotype of 
GSTM1/GSTT1 is significantly associated with an 
increased risk of renal cell carcinoma (Jia et al., 
2014). However, deletion polymorphism of GSTM1 
does not contribute individually to susceptibility to 
renal cell carcinoma (Yang et al., 2013; Salinas-
Sánchez et al., 2012) 
Bladder cancer 
Recent investigation indicates that the GSTM1-null 
genotype in combination with the GSTA1-low 
activity genotype significantly increases the risk of 
bladder cancer in smokers (Matic et al., 2013). In 
addition, it seems that GSTM1-null and GSTA1-low 
activity genotypes are associated with enhanced 
oxidative damage in bladder cancer (Savic-
Radojevic et al., 2013). Furthermore, latest results of 
Wang et al. (2014) suggested that GSTM1-null 
genotype is among seven bladder cancer risk-
associated variants (rs9642880, rs2294008, 
rs798766, rs1495741, GSTM1-null, rs17674580 and 
rs10936599) that may be used, collectively, to 
effectively measure inherited risk for bladder cancer. 
Prostatic cancer 
It has been shown that GSTM1 gene polymorphism 
contributes to prostatic cancer susceptibility (Cai et 
al., 2014). Furthermore, Chen et al. (2013) identified 
a possible association between GSTM1-null 
genotype and prostate cancer recurrence risk with 
borderline significance. As suggested by Acevedo et 
al. (2014), GSTM1-active genotype may also be a 
good prognosis marker, particularly in patients with 
high-risk tumors. 
Ovarian cancer 
Available meta-analysis show that GSTM1-null 
genotype is not associated with ovarian cancer risk 
(Yin et al., 2013; Xu et al., 2014). 
Leukemia 
Results of recent meta-analysis suggested that 
heritable GST status could influence the risk of 
developing acute myeloid leukemia, based on the 
finding that the GSTM1-null genotype was 
associated with an increased risk of acute myeloid 
leukemia in East Asians, with a predilection towards 
the female gender. Furthermore, the double-null 
genotypes (GSTM1-null and GSTT1-null) increased 
the risk of acute myeloid leukemia in both 
Caucasians and East Asians (He et al., 2014). 
Regarding chronic myeloid leukemia, Banescu et al. 
(2014) found no association with susceptibility to 
this type of leukemia. 
Melanoma 
The results reported in the latest meta-analysis 
suggested that the GSTM1 polymorphism is not a 
risk factor for developing melanoma (Nie et al., 
2011). On the other hand, the association has been 
shown between GSTM1-null and GSTT1-null 
genotypes and sunburns in childhood. Namely, it has 
been suggested that carriers of GSTM1-null and 
GSTT1-null genotypes, with history of sunburns in 
childhood, are in increased risk of melanoma (Fortes 
et al., 2011). 
Basal cell carcinoma and squamous 
cell carcinoma 
Available data suggest that GSTM1 polymorphism 
is not associated with risks of basal and squamous 
cell carcinomas (Peng et al., 2013). 
Thyroid cancer 
Regarding the role of GSTM1 polymorphism in the 
risk of thyroid cancer, the results are still 
inconclusive.  
Several studies found the GSTM1-null genotype to 
be associated with an increased risk of thyroid 
cancer, while some showed protective effect or lack 
of association.  
However, the latest meta-analysis suggested that 
GSTM1-null genotype does not affect susceptibility 
to thyroid cancer (Li et al., 2012; Gonalves et al., 
2009). 
Colorectal cancer 
Regarding the role of GSTM1 polymorphism in 
colorectal cancer, results of comprehensive meta-
analysis conducted on forty-four studies (11,998 
colorectal cancer cases, 17,552 controls) showed that 
GSTM1-null allele carriers exhibit increased 
colorectal cancer risk in Caucasian population, while 
no significant association was detected for Chinese 
subjects (Economopoulos and Sergentanis, 2010).  
When analyzed with respect to smoking, no 
interactions between GSTM1/smoking and 
colorectal cancer risk have been reported. One polyp 
study suggests an interaction between GSTM1 
genotype and smoking (Cotton et al., 2000). 
Glaucoma 
In their meta-analysis, Huang et al. (2013) suggested 
that GSTM1-null genotype is associated with 
increased primary open-angle glaucoma risk in 
Asian populations, but not in Caucasian and mixed 
populations. Furthermore, dual null genotype of 
GSTM1/GSTT1 is also associated with increased 
risk of primary open-angle glaucoma (Huang et al., 
2013). 
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Endometriosis 
Available data suggest increased risk for 
development of endometriosis among Caucasians 
and Asians, carriers of GSTM1-null genotype (Ding 
et al., 2014). 
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